{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:58:50Z","timestamp":1768474730951,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010355","name":"Hellenic Society of Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010355","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.clinbiochem.2018.07.008","type":"journal-article","created":{"date-parts":[[2018,7,29]],"date-time":"2018-07-29T07:33:52Z","timestamp":1532849632000},"page":"24-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance"],"prefix":"10.1016","volume":"60","author":[{"given":"Emmanuel I.","family":"Papadopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Papachristopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Ardavanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Scorilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0005","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/annonc\/mdw022","article-title":"European cancer mortality predictions for the year 2016 with focus on leukaemias","volume":"27","author":"Malvezzi","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0015","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0020","doi-asserted-by":"crossref","first-page":"c3620","DOI":"10.1136\/bmj.c3620","article-title":"Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database","volume":"341","author":"Autier","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0025","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1200\/JCO.2015.65.2289","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline","volume":"34","author":"Harris","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.clinbiochem.2018.07.008_bb0030","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"3rd ESO-ESMO International consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0040","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0045","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0050","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1007\/s13277-015-3944-7","article-title":"Breast cancer circulating biomarkers: advantages, drawbacks, and new insights","volume":"36","author":"Ravelli","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0055","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","article-title":"MicroRNAs in cancer: biomarkers, functions and therapy","volume":"20","author":"Hayes","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0060","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrg3965","article-title":"Towards a molecular understanding of microRNA-mediated gene silencing","volume":"16","author":"Jonas","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0065","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1160\/TH08-01-0037","article-title":"Expression analysis and study of KLK4 in benign and malignant breast tumours","volume":"101","author":"Papachristopoulou","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0070","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1515\/hsz-2017-0122","article-title":"Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer","volume":"398","author":"Yang","year":"2017","journal-title":"Biol. Chem."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0075","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1515\/hsz-2011-0246","article-title":"The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer","volume":"393","author":"White","year":"2012","journal-title":"Biol. Chem."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0080","doi-asserted-by":"crossref","first-page":"14895","DOI":"10.18632\/oncotarget.24473","article-title":"Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer","volume":"9","author":"Lian","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.molonc.2013.10.001","article-title":"High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth","volume":"8","author":"Leivonen","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0090","series-title":"WHO Classification of Tumours of the Breast","author":"Lakhani","year":"2012"},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0100","series-title":"TNM Classification of Malignant Tumours","author":"Sobin","year":"2009"},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0105","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0110","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1515\/hsz-2015-0284","article-title":"Clinical evaluation of microRNA-145 expression in renal cell carcinoma: a promising molecular marker for discriminating and staging the clear cell histological subtype","volume":"397","author":"Papadopoulos","year":"2016","journal-title":"Biol. Chem."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0130","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0135","doi-asserted-by":"crossref","first-page":"24696","DOI":"10.1074\/jbc.M109.030098","article-title":"miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer","volume":"284","author":"Epis","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0140","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1476-4598-13-92","article-title":"Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer","volume":"13","author":"Liu","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0145","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3892\/or.2015.4450","article-title":"MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K\/Akt and ERK1\/2 pathways in colorectal cancer","volume":"35","author":"Zhao","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0150","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1440-1827.1994.tb01687.x","article-title":"Invasive ductal carcinoma with a predominant intraductal component arising in a fibroadenoma of the breast","volume":"44","author":"Kurosumi","year":"1994","journal-title":"Pathol. Int."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s10147-004-0401-9","article-title":"Invasive ductal carcinoma within a fibroadenoma of the breast","volume":"9","author":"Abe","year":"2004","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1757-1626-2-174","article-title":"Invasive ductal carcinoma within fibroadenoma: a case report","volume":"2","author":"Gashi-Luci","year":"2009","journal-title":"Cases J."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/IJGM.S26115","article-title":"Invasive ductal carcinoma within fibroadenoma and lung metastases","volume":"5","author":"Abu-Rahmeh","year":"2012","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0170","first-page":"366","article-title":"Mucinous subtype of invasive ductal carcinoma arising within a fibroadenoma","volume":"16","author":"Monsefi","year":"2013","journal-title":"Arch. Iran. Med."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5152\/tjbh.2015.2417","article-title":"Invasive ductal carcinoma developing from fibroadenoma","volume":"11","author":"Ayd\u0131n","year":"2015","journal-title":"J. Breast Health"},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0180","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/tbj.12666","article-title":"Invasive ductal carcinoma displayed \"basal-like\" feature arising within a breast fibroadenoma","volume":"22","author":"Ma","year":"2016","journal-title":"Breast J."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0185","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4103\/0973-1482.73350","article-title":"Ductal carcinoma in a multiple fibroadenoma: diagnostic inaccuracies","volume":"6","author":"Rao","year":"2010","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.clinbiochem.2018.07.008_bb0190","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.gene.2014.10.043","article-title":"Human l-DOPA decarboxylase mRNA is a target of miR-145: a prediction to validation workflow","volume":"554","author":"Papadopoulos","year":"2015","journal-title":"Gene"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912018303394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912018303394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:53:15Z","timestamp":1757865195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912018303394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":38,"alternative-id":["S0009912018303394"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.07.008","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists.","name":"copyright","label":"Copyright"}]}}